NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

RecruitingPhase 3

Sponsor: Eli Lilly and Company

Conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

Interventions: Orforglipron, Placebo

Countries: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Eligibility overview

Sex: ALL

Age: 50 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Have established ASCVD and/or CKD

Exclusion Criteria:

* Have type 1 diabetes
* Have had a major heart condition within 60 days prior to screening
* Have New York Heart Association Functional Classification Class IV heart failure

Locations (567)

Bahía Blanca, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
C.a.b.a., Argentina
CABA, Argentina
Corrientes, Argentina
Córdoba, Argentina
Córdoba, Argentina
Córdoba, Argentina
Córdoba, Argentina
Córdoba, Argentina
Esperanza, Argentina
Godoy Cruz, Argentina
Granadero Baigorria, Argentina
+ 537 more on CT.gov